Acquired (Autoimmune) Hemolytic Anemia - Pipeline Review, H2 2011


November 28, 2011
36 Pages - SKU: GMD6691643
License type:
Table of Contents Search inside this report Related Reports
Introduction
Global Markets Direct Report Coverage
Acquired (Autoimmune) Hemolytic Anemia Overview
Therapeutics Development
An Overview of Pipeline Products for Acquired (Autoimmune) Hemolytic Anemia
Acquired (Autoimmune) Hemolytic Anemia Therapeutics under Development by Companies
Acquired (Autoimmune) Hemolytic Anemia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Acquired (Autoimmune) Hemolytic Anemia Therapeutics - Products under Development by Companies
Acquired (Autoimmune) Hemolytic Anemia Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Acquired (Autoimmune) Hemolytic Anemia Therapeutics Development
Accentia Biopharmaceuticals, Inc.
Acquired (Autoimmune) Hemolytic Anemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Revimmune - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Filgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mabthera - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prednisolone + Mabthera - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab + Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acquired (Autoimmune) Hemolytic Anemia Therapeutics - Drug Profile Updates
Acquired (Autoimmune) Hemolytic Anemia - Featured News
Jun 23, 2011: FDA Grants Orphan Drug Status For Accentia's Revimmune Therapy In Systemic Sclerosis And Hemolytic Anemia
Jun 11, 2011: Alexion Presents Additional Data At EHA Congress Describing Long-Term Efficacy And Survival Data With Sustained Soliris Therapy
May 23, 2011: Researchers To Present Nine Studies On Alexion's Soliris In Patients With PNH And aHUS At EHA Congress
Feb 28, 2007: Accentia Biopharmaceuticals Acquires Worldwide Exclusive License To Revimmune
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Acquired (Autoimmune) Hemolytic Anemia, H2 2011
Products under Development for Acquired (Autoimmune) Hemolytic Anemia - Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Accentia Biopharmaceuticals, Inc., H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Acquired (Autoimmune) Hemolytic Anemia Therapeutics - Drug Profile Updates
List of Figures
Number of Products under Development for Acquired (Autoimmune) Hemolytic Anemia, H2 2011
Products under Development for Acquired (Autoimmune) Hemolytic Anemia - Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011
 
Research assistance
We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 
Related Markets

Drug Discovery Reports
 
 

Share this report


Other tasks

 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!